• Tech
  • Business
  • London
  • Legal & Compliance
  • Pharma & Biotech
  • International

Mobile Logo

David H. Shepardson

David primarily covers financial and business news at London Insider, including high-growth tech stocks and the volatile crypto markets.

September 14, 2026
Latest News

FTSE 100 Climbs As Oil Surges On Middle East Supply Fears And Hormuz Uncertainty

London’s benchmark index edged higher on Monday as rising oil prices driven by Middle East supply disruptions lifted sentiment across UK markets. The FTSE 100 gained 0.53% as of 03:15 ET, while

Latest News

S&P 500 Futures Signal Mixed Open As Investors Weigh Economic Outlook

The S&P 500 remains a closely watched benchmark for global investors, with daily movements reflecting broader sentiment across equities markets in the United States. Futures trading ahead of each session gives investors an early indication of whether the index is

September 14, 2026

AI Safety Warnings From Industry Leaders Send Tech Stocks Tumbling Across Asia And US Futures

Latest News

Japan’s SoftBank (9984.T), one of OpenAI’s biggest investors, plunged as much as 13 per cent in Tokyo trading on Monday amid a broad technology

Oil Surges To Four-Month High As Trump Signals US May “Keep” Iran’s Oil Supply

Latest News

Brent crude climbed sharply toward $108 per barrel on Monday morning, reaching its highest level in four months after a significant supply disruption in

Latest News

FTSE 100 (LSE:UKX) Climbs 87 Points As Wall Street Rises Following In-Line US Inflation Data

London’s blue-chip index pushed steadily higher through Friday’s session, rising 87 points to 10,695 after starting the day just 6 points above Thursday’s close. The FTSE 100 ended a five-day losing streak,

More
by David H. Shepardson
September 13, 2026
Latest News

Genus (GNS) Shares Present Buying Opportunity Amid Recent Price Weakness

Genus (GNS), the animal genetics company listed on the London Stock Exchange, has seen its share price come under pressure, prompting analysts to flag a potential entry point for investors. The stock

More
by David H. Shepardson
September 13, 2026
Latest News/Pharma & Biotech

Merck And Gilead’s Failed Lung Cancer Trial Data Sparks Fresh Debate On Chinese Clinical Research Validity In Western Markets

The full phase 3 dataset from Merck (MRK) and Gilead’s (GILD) failed Trodelvy trial in first-line non-small cell lung cancer has now been made public, raising significant questions for the industry. The

More
by David H. Shepardson
September 13, 2026
Latest News/Legal & Compliance

Maryland Franchise Law Amendments Take Effect October 1, Bringing Sweeping Changes For Franchisors

Maryland has amended its Maryland Franchise Registration and Disclosure Law, with all changes coming into effect on October 1, 2026, reshaping obligations for franchisors operating in the state. Franchisors registered in Maryland

More
by David H. Shepardson
September 13, 2026
Latest News/Legal & Compliance

Weil, Gotshal Loses Corporate Chair Michael Aiello To Cravath In Major Partner Raid

Weil, Gotshal & Manges has suffered a significant departure as Michael Aiello, chair of its roughly 600-lawyer corporate department, heads to rival firm Cravath, Swaine & Moore. Aiello also holds a seat

More
by David H. Shepardson
September 13, 2026
Latest News

Deere & Company (DE) Shares Could Be Trading At An 11% Discount As Sector Recovery Builds

Deere & Company (DE) appears to be trading at a significant discount to its estimated fair value, with analysts suggesting shares may be undervalued by as much as 11%. The agricultural and

More
by David H. Shepardson
September 13, 2026
Latest News

iShares FTSE 250 ETF Announces Latest Dividend Declaration

iShares FTSE 250, the exchange-traded fund tracking mid-cap UK listed companies, has announced a new dividend declaration for its sterling share class. The fund, managed by BlackRock (BLK), is one of the

More
by David H. Shepardson
September 12, 2026
Latest News/Pharma & Biotech

AstraZeneca (AZN) Oral SERD Etcamah Fails First-Line Breast Cancer Trial, Shares Slide 3%

AstraZeneca’s (AZN) camizestrant, branded Etcamah, has failed to demonstrate a statistically significant improvement in a major Phase III breast cancer trial, dealing a blow to the drug’s broader commercial ambitions. The SERENA-4

More
by David H. Shepardson
September 12, 2026
Latest News/Legal & Compliance

IEEPA Tariff Refunds Face New Delays As Importers Urged To File Lawsuits Before Deadlines

The Supreme Court’s decision to strike down International Emergency Economic Powers Act tariffs triggered a major refund process, but new complications are emerging for importers across the United States. US Customs and

More
by David H. Shepardson
September 12, 2026
Latest News/Legal & Compliance

First Circuit Opinion Using “Deets” Sparks Debate Over Informal Legal Writing Style

A federal appellate opinion from the First Circuit has drawn widespread attention for its strikingly casual writing style, prompting debate across the legal community. The opinion, written by Judge O. Rogeriee Thompson,

More
by David H. Shepardson
September 12, 2026
Previous 1 2 3 4 5 … 274 Next

Why Trump Signed an Executive Order Declaring National Emergency Over Foreign Bulk Power Equipment

Inside Five Street Challenges LiDAR Helps Cities Understand and Solve

London Insider © 2026 - All Rights Reserved. London Insider is a leading UK-headquartered news publication, covering financial news, tech and more.

  • Home
  • About Us
  • Tourist Guide
  • Advertise
  • Contact Us
  • Tech
  • Business
  • London
  • Legal & Compliance
  • Pharma & Biotech
  • International